share_log

醫思健康:截至2024年2月29止月份之股份發行人的證券變動月報表

EC HEALTHCARE: Monthly Return of Equity Issuer on Movements in Securities Ended 29 February 2024

香港交易所 ·  Mar 5 04:41
Summary by Moomoo AI
醫思健康(EC HEALTHCARE)於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,涵蓋截至2024年2月29日的情況。報告顯示,公司的法定/註冊股本維持不變,總額為380,000港元,每股面值為0.00001港元,總股份數目為38,000,000,000股。此外,報告詳述了公司股份期權計劃的變動,包括2016年2月19日及2023年5月29日通過的購股權計劃,以及OrbiMed和GS的認股權證和可換股債券的詳情。報告中未顯示本月內有任何股份期權行使,因此沒有新股份發行。公司確認所有證券發行均已獲得董事會批准,並符合香港聯合交易所有限公司證券上市規則的相關要求。
醫思健康(EC HEALTHCARE)於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,涵蓋截至2024年2月29日的情況。報告顯示,公司的法定/註冊股本維持不變,總額為380,000港元,每股面值為0.00001港元,總股份數目為38,000,000,000股。此外,報告詳述了公司股份期權計劃的變動,包括2016年2月19日及2023年5月29日通過的購股權計劃,以及OrbiMed和GS的認股權證和可換股債券的詳情。報告中未顯示本月內有任何股份期權行使,因此沒有新股份發行。公司確認所有證券發行均已獲得董事會批准,並符合香港聯合交易所有限公司證券上市規則的相關要求。
EC HEALTHCARE SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON MARCH 5, 2024, COVERING THE SITUATION AS OF FEBRUARY 29, 2024. The report showed that the company's regulated/registered share capital remained unchanged, totalling HK$380,000, with a face value of HK$0.00001 per share and a total number of shares of 38,000,000,000 shares. In addition, the report details changes to the Company's stock option plans, including the share option plans adopted on February 19, 2016 and May 29, 2023, and details of the warrants and convertible notes for OrbiMed and GS. The report did not show any exercise of stock options during the month, so no new shares were issued. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
EC HEALTHCARE SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON MARCH 5, 2024, COVERING THE SITUATION AS OF FEBRUARY 29, 2024. The report showed that the company's regulated/registered share capital remained unchanged, totalling HK$380,000, with a face value of HK$0.00001 per share and a total number of shares of 38,000,000,000 shares. In addition, the report details changes to the Company's stock option plans, including the share option plans adopted on February 19, 2016 and May 29, 2023, and details of the warrants and convertible notes for OrbiMed and GS. The report did not show any exercise of stock options during the month, so no new shares were issued. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more